Privia Health Group, Inc.

Privia Health Group, Inc. (PRVA) Market Cap

Privia Health Group, Inc. has a market capitalization of $2.70B.

Price: $21.41

-0.22 (-1.02%)

Market Cap: 2.70B

NASDAQ · time unavailable

CEO: Parth Mehrotra

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2021-04-28

Website: https://www.priviahealth.com

Privia Health Group, Inc. (PRVA) - Company Information

Market Cap: 2.70B|Sector: Healthcare

Company Profile

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. was a former subsidiary of Brighton Health Group Holdings, LLC.

Analyst Sentiment

90%
Strong Buy

From 22 Active Polls

1Y Forecast: $30.00

▲ +40.1% Potential Upside

Consensus Target Metrics

Low Bound

$24

Median

$31

High Bound

$36

Average

$30

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$30.00
▲ +40.12% Upside
Low Target
$24.00
12% Risk
Median Target
$31.00
45% Mid
High Target
$36.00
68% Max
Consensus
Buy
20 / 22 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)2,6982,5542,9213,0572,8092,7082,3492,1792,040
Enterprise Value ($M)2,2872,1432,4512,6222,4262,2441,8631,7631,659
Price to Earnings Ratio (P/E)122.14208.3779.79111.39261.35160.43133.48154.10147.11
Price/Earnings-to-Growth Ratio (PEG)17.999.7930.5638.5225.4441.7386.24
Price to Sales Ratio (P/S)1.204.235.405.275.395.645.104.984.83
Price to Book Ratio (P/B)3.533.393.964.314.114.113.703.543.43
Price to Free Cash Flow Ratio (P/FCF)19.73-51.6022.9160.18352.41-112.5531.4065.7259.19
Enterprise Value to Sales (EV/Sales)3.554.534.524.654.674.044.033.93
Enterprise Value to EBITDA (EV/EBITDA)43.65200.25175.86134.87291.29315.23263.15231.69239.94
Debt to Equity Ratio-7.830.010.010.010.010.010.010.010.01

PRVA Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$21.41
Intrinsic Value$32.27
Market Alignment
Undervalued by 50.7%relative to calculated intrinsic value
9.00%
Exp: 7%7%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.28B
Perpetuity TV Value$5.19B
Discounted TV (PV)$2.19B
TV Weighting %62.4%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PRIVIA HEALTH GROUP INC (PRVA) — Investment Overview

🧩 Business Model Overview

Privia Health Group operates as a physician enablement platform focused on value-based care and payer-facing care management. The company’s core “how it works” centers on aligning incentives and infrastructure across independent physician practices: (1) technology and operational support for clinical documentation, care coordination, and performance reporting; (2) care management workflows that improve chronic-disease outcomes and reduce avoidable utilization; and (3) contracting capabilities that help practices participate in risk- and quality-based arrangements with payers. Over time, Privia’s model benefits from the operational integration of practices into a standardized ecosystem, allowing consistent measurement, reporting, and execution across a large footprint.

The practical outcome is a service delivery and data layer that reduces friction for practices to operate under modern reimbursement structures while giving payers greater confidence in quality metrics and cost-control performance.

💰 Revenue Streams & Monetisation Model

Monetisation is primarily driven by recurring fees for operational and technology support and by value-based care-related economics tied to quality and utilization. Revenue composition typically includes:

  • Recurring practice/technology support: ongoing subscription-style or per-unit arrangements for software-enabled services, administrative tooling, and care coordination capabilities.
  • Value-based and performance components: economics linked to outcomes, quality performance, and/or care delivery under risk or shared-savings frameworks.
  • Transactional services embedded within care delivery: services that scale with care volume and program participation, though the long-term goal is a higher mix of recurring, platform-driven economics.

Margin drivers generally relate to (1) the scalability of the technology and care management operating model, (2) the ability to manage medical cost trends through clinical protocols and analytics, and (3) operational leverage as the platform supports more practices and attributed lives without proportionate increases in overhead.

🧠 Competitive Advantages & Market Positioning

Moat: Switching costs and integrated ecosystem built around performance reporting.

  • High switching costs (workflow + operational integration): once a practice’s documentation, clinical workflows, performance tracking, and payer reporting processes run through Privia’s support layer, replacing the ecosystem is operationally disruptive and costly. The switching barrier is reinforced by the practical need to maintain continuity in reporting and care-management protocols.
  • Integrated ecosystem (data gravity + performance measurement): Privia’s platform standardizes clinical and operational processes, enabling consistent measurement of quality indicators and care patterns across practices. That standardization improves execution and makes it harder for competitors to replicate outcomes without comparable implementation depth.
  • Payer/customer “confidence” as a durable asset: consistent reporting and care-management execution under value-based arrangements can increase payer willingness to expand contracts, creating a reinforcing loop between performance and scaling opportunities.

Competitive benchmarking (primary peers):

  • Aledade (ACO enablement for independent physician practices): both pursue value-based care enablement, but Privia’s emphasis on integrating broader operational/technology support and scaling through a larger service ecosystem shapes its competitive profile.
  • Optum (UnitedHealth Group) (care delivery and value-based services): Optum competes with scale and payer relationships; Privia’s differentiator is enabling and standardizing physician practice operations in a manner tailored to smaller, fragmented care settings.
  • Oak Street Health (value-focused primary care delivery): Oak Street is more delivery-centric with clinic operations, while Privia leans toward practice enablement and payer-aligned infrastructure across a wider physician footprint.

Against these rivals, Privia’s positioning is centered on making independent practices operationally capable under value-based reimbursement through technology-enabled care management and performance reporting—an angle that depends less on owning fixed site capacity and more on scalable integration.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, Privia’s growth can be supported by durable demand drivers that favor platform-based value-based care enablement:

  • Secular shift toward value-based reimbursement: payers increasingly seek measurable quality and cost outcomes, raising demand for standardized care-management and reporting infrastructure.
  • Medicare Advantage and risk-based contracting expansion: as government and commercial payers broaden risk arrangements, physician support models that can operate under performance accountability gain relevance.
  • Chronic disease management needs: aging demographics and rising chronic-care utilization increase the value of structured care pathways, analytics, and proactive care coordination.
  • Data-driven care operations: the industry continues to move toward performance measurement, documentation quality, and outcome tracking—areas where integrated ecosystems can produce incremental efficiencies.
  • Practice fragmentation economics: the U.S. physician market remains fragmented; platform providers that can standardize operations across independent groups can expand through “onboard and replicate” implementations.

⚠ Risk Factors to Monitor

  • Regulatory and reimbursement risk: changes to CMS rules, Medicare Advantage risk adjustments, and value-based program design can alter economics, quality requirements, or the feasibility of risk-based participation.
  • Execution and integration risk: scaling physician practices requires disciplined onboarding, change management, and adherence to clinical and documentation protocols; underperformance can pressure margins and payer confidence.
  • Cybersecurity and data privacy: a technology-enabled healthcare model depends on robust protection of sensitive health information and continuity of digital operations.
  • Medical cost trend and risk-bearing economics: where contracts include risk or shared savings, adverse utilization or coding/documentation mismatches can reduce profitability.
  • Concentration and contract dynamics: payer contract terms and renewal outcomes can materially influence revenue mix and profitability.

📊 Valuation & Market View

Market valuation for healthcare services/platform models typically focuses on the durability and visibility of earnings, not just growth. Investors often benchmark on metrics such as EV/Revenue or EV/EBITDA, with premium valuation associated with:

  • Recurring revenue quality: higher recurring mix tied to services and technology support can stabilize results versus purely transactional models.
  • Evidence of operational leverage: improving margins as scale increases suggests the platform is producing sustainable cost efficiencies.
  • Quality/performance credibility: demonstrated execution under value-based arrangements can support multiple expansion through lower perceived contract-risk.
  • Managed lives / practice scale growth: scale can drive better unit economics when implementation costs do not rise proportionally.

Key valuation sensitivities usually include the pace of practice and contract expansion, the mix between recurring support and value-based performance components, and any changes in reimbursement policy that affect shared-savings or risk economics.

🔍 Investment Takeaway

Privia’s long-term case rests on a structural shift toward value-based care and on a defensible operating model that creates switching costs through workflow integration and data-driven performance measurement. The company’s integrated ecosystem can support scaled physician enablement while meeting payer demands for measurable quality and cost control. The investment merits align with sustained industry adoption of value-based contracting, tempered by reimbursement, execution, and medical cost trend risks that warrant ongoing monitoring.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for PRVA.

fool.com2026-06-08

Privia's CEO Just Sold 121,000 Shares for $2.7 Million

CEO Parth Mehrotra sold 121,086 shares directly for a total of ~$2.73 million at an average price of around $22.56 per share across two days ending May 12, 2026. This transaction represented 21.80% of Mehrotra's direct holdings prior to the sale, reducing his direct position to 434,357 shares.

gurufocus.com2026-06-04

A Look at Privia Health Group Inc (PRVA) After 3.4% Gain -- GF Value $27.19 vs Price $21.37

On June 04, 2026, Privia Health Group Inc (PRVA) shares rose 3.4% to a current price of $21.37. Over the past 52 weeks, the stock has traded between $18.77 and

fool.com2026-05-30

Is Privia Health Stock a Buy After Hedge Fund Rubicon Founders Added Over 175,000 Shares to Its Position?

Privia Health Group delivers technology-driven solutions to optimize physician practices and support value-based care nationwide.

globenewswire.com2026-05-28

Cross Keys Capital Advises Neurology Group of Bergen County in Its Partnership with Privia Health

Fort Lauderdale, May 28, 2026 (GLOBE NEWSWIRE) -- Cross Keys Capital, LLC, a leading independent investment banking firm providing M&A advisory services to physician group practices and healthcare services companies,is  pleased to announce it acted as the exclusive financial advisor to the Neurology Group of Bergen County (“NGBC”) in its partnership with Privia Health. Founded in 1973, the Neurology Group of Bergen County is one of the region's most respected independent neurology practices, serving the communities of Bergen County, New Jersey.

zacks.com2026-05-27

TBRG vs. PRVA: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Info Systems sector might want to consider either TruBridge (TBRG) or Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?

globenewswire.com2026-05-27

Privia Health Enters New Jersey

ARLINGTON, Va., May 27, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA), a national physician enablement company, announced it has signed a definitive agreement to enter the state of New Jersey in partnership with Neurology Group of Bergen County (NGBC), a practice with 25 adult and pediatric clinicians.

zacks.com2026-05-11

TBRG or PRVA: Which Is the Better Value Stock Right Now?

Investors interested in Medical Info Systems stocks are likely familiar with TruBridge (TBRG) and Privia Health (PRVA). But which of these two stocks presents investors with the better value opportunity right now?

marketbeat.com2026-05-08

Privia Health Group Q1 Earnings Call Highlights

Privia Health Group NASDAQ: PRVA reported a strong first quarter, with executives pointing to double-digit provider growth, a larger value-based care population and margin expansion as signs that the company's operating model continues to scale.

seekingalpha.com2026-05-08

Privia Health Group, Inc. (PRVA) Q1 2026 Earnings Call Transcript

Privia Health Group, Inc. (PRVA) Q1 2026 Earnings Call Transcript

zacks.com2026-05-07

Privia Health (PRVA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com2026-05-07

Privia Health (PRVA) Misses Q1 Earnings Estimates

Privia Health (PRVA) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.03 per share a year ago.

globenewswire.com2026-05-07

Privia Health Reports First Quarter 2026 Financial Results

Privia Health Reports First Quarter 2026 Financial Results; Strong First Quarter Performance and Operating Execution; Reiterated Full-Year 2026 Guidance

globenewswire.com2026-04-08

Privia Health to Report First Quarter 2026 Results on Thursday, May 7

ARLINGTON, Va., April 08, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its first quarter ended March 31, 2026 before market open on Thursday, May 7, 2026.

defenseworld.net2026-04-04

JPMorgan Chase & Co. Acquires 30,845 Shares of Privia Health Group, Inc. $PRVA

JPMorgan Chase and Co. increased its holdings in Privia Health Group, Inc. (NASDAQ: PRVA) by 26.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,709 shares of the company's stock after acquiring an additional 30,845 shares during

globenewswire.com2026-03-24

Privia Health Earns 2026 HFMA MAP Award for Revenue Cycle Excellence

ARLINGTON, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of affiliated medical groups, collectively Privia Medical Group, has been named a recipient of the 2026 MAP (Measure, Apply, Perform) Award for High Performance in Revenue Cycle, sponsored by the Healthcare Financial Management Association (HFMA).

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"PRVA reported Q1’26 revenue of $603.8M and net income of $3.1B (EPS $0.02). On a YoY basis, revenue rose from $480.1M in Q1’25 to $603.8M (+25.8% YoY), while net income increased from $4.2M to $3.1B (very large +~72,000% YoY). Sequentially (QoQ), revenue grew from $541.2M in Q4’25 to $603.8M (+11.6% QoQ), and net income jumped from $9.2M to $3.1B (up sharply QoQ). Profitability was mixed: operating income was only $7.4M (operating margin ~1.2%), yet net margin shows 5.1% in Q1’26, implying substantial below-the-line or one-time effects versus Q4’25 net margin of ~1.7%. Over the last four reported quarters, operating margins generally trended higher from Q2’25 (~0.6%) through Q4’25 (~2.1%), then remained modest in Q1’26 (~1.2%). Cash flow deteriorated materially in Q1’26, with operating cash flow of -$49.5M and free cash flow of -$49.5M, versus positive operating cash flow in Q4’25 (+$127.5M). Balance sheet strength remains notable for scale, with total assets ~ $1.42B and net cash (net debt -$410.5B shown) supported by very large cash & equivalents ($419.5B). Total shareholder return is not captured by buybacks/dividends (none reported). Market performance shows the stock at $24.02 with only +0.63% over 1 year—momentum is not strong. Analyst valuation context includes a consensus target of ~$31.67 versus $24.02 current."

Revenue Growth

Positive

Revenue increased to $603.8M in Q1’26 (+25.8% YoY) and rose +11.6% QoQ from $541.2M in Q4’25, indicating accelerating top-line momentum.

Profitability

Caution

Operating margin was modest (~1.2%) in Q1’26; despite net income surging to $3.1B, the pattern suggests net results may be driven by below-operating effects. Prior quarters showed lower operating margins (Q2’25 ~0.6%, Q4’25 ~2.1%).

Cash Flow Quality

Neutral

Q1’26 operating cash flow was -$49.5M (free cash flow -$49.5M), versus +$127.5M in Q4’25—quality weakened sequentially.

Leverage & Balance Sheet

Neutral

Total assets increased to ~$1.42B from ~$1.37B QoQ. Liquidity appears very strong with cash & equivalents of ~$419.5B; debt is low (short-term debt ~$2.1B, long-term debt ~$6.9B). Equity is sizable (total stockholders’ equity ~$753.1M).

Shareholder Returns

Caution

No dividends or buybacks reported. Total return is therefore primarily dependent on price; 1Y performance is only +0.63% (no >20% momentum boost).

Analyst Sentiment & Valuation

Neutral

Consensus target is ~$31.67 versus current ~$24.02 (upside implied). Price/earnings metrics appear difficult to interpret given volatile earnings base in Q1’26.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

PRVA delivered strong Q1 execution with broad-based growth: implemented providers rose 13.6% YoY to 5,535 and practice collections climbed 14.6% YoY to $914.8M. The quality of growth showed up in profitability—adjusted EBITDA grew 36.3% YoY to $36.7M and EBITDA margin expanded 290 bps to 28.5% of care margin. Attribution accelerated to 1.6M lives (+26.5% YoY), aided by Evolent ACO integration, with CMS Medicare attributed lives up 62% and MA/Medicaid attribution up 20%/36%. Management reiterated 2026 guidance on most metrics while raising the attributed-lives range, implying confidence in continued operating leverage and ~80% EBITDA-to-free-cash-flow conversion. In Q&A, they emphasized MA’s tailwinds while maintaining a shared-risk stance, highlighted minimal ambulatory impact from respiratory/flu season variability, and framed near-term guidance as potentially subject to typical early-year puts and takes.

AI IconGrowth Catalysts

  • Implemented provider growth to 5,535 (+13.6% YoY) supporting practice collections of $914.8M (+14.6% YoY)
  • Attribution growth to 1.6M value-based attributed lives (+26.5% YoY), including Evolent ACO addition
  • EBITDA margin expansion: EBITDA as % of care margin up 290 bps to 28.5%
  • Medicare momentum: CMS Medicare attributed lives up 62% and MA/Medicaid attribution up 20%/36%

Business Development

  • Addition of the Evolent ACO business (contributing to 26.5% attribution growth and “ahead on integration” per Q&A)
  • Commercial and government contracts totaling 130+ (platform serves 1.6M patients across 24 states + DC)

AI IconFinancial Highlights

  • Adjusted EBITDA increased 36.3% YoY to $36.7M; EBITDA margin reached 28.5% of care margin (+290 bps)
  • Practice collections increased 14.6% YoY to $914.8M
  • Cash and balance sheet: $219.5M cash at quarter-end; no debt
  • Guidance approach: reiterated 2026 guidance metrics, except raising the attributed-lives range at year-end
  • Cash conversion guidance: convert ~80% of full-year EBITDA to free cash flow as they become a full cash taxpayer
  • No specific EPS or explicit beat/miss stated in transcript; shared savings discussion indicates strength but not quantified

AI IconCapital Funding

  • Share repurchase/noncontrolling interest buyback: $11M repurchase of NCI in the quarter (acquired minority interests in some markets)
  • No debt; Q1 cash of $219.5M
  • Year-end cash reference: analysts cited ~$600M cash at year-end; management implied guidance remains unchanged and cash + free cash flow should approximate that level (excluding BD/acquisitions)

AI IconStrategy & Ops

  • Technology leadership: hired Chief Technology Officer Konda from Optum Insights; Chris Foy retired
  • AI deployment plan across three buckets: (1) Privia Enterprise/corporate functions, (2) care center operations/workflows, (3) care delivery clinical workflows
  • AI/automation examples cited: autonomous coding, prior auth, referral management; value-based workflows like care gap closures, chart prep, patient scheduling, and patient interaction/agentic AI outreach
  • Margin framing: already approaching low end of long-term margin target (EBITDA-to-care margin 30–35%); 2026 guidance expected near ~29%, with AI expected to push toward upper end over 5 years

AI IconMarket Outlook

  • 2026 outlook maintained on most metrics; only attributed-lives range raised (no numeric range given in transcript)
  • Commentary on shared savings: management expects shared savings should not be flat YoY if early-year trend continues, but prior-period “dry period” mix effects may normalize over subsequent quarters

AI IconRisks & Headwinds

  • Guidance conservatism/puts-and-takes: management highlighted that early-year guidance may be adjusted as more data emerges quarter-to-quarter
  • Policy/regulatory uncertainty: Medicare Advantage program changes (V28) and CMS program adjustments could alter contracting mechanics by geography
  • Program-level risk and volatility acknowledged: commercial open-access product limits risk take; shared savings volatility vs government programs not quantified
  • Sales/implementation timing risk: 3–6 month sales cycles and 4–6 month implementation cycles imply ramp/visibility depends on conversion cadence

Q&A: Analyst Interest

  • Shared savings and guidance puts/takes: Management said they keep executing each quarter and adjust guidance only as more data becomes available; they noted they don’t expect shared savings to be flat if the current trend continues, but prior-period items could influence results until more data is known.
  • Medicare Advantage and capitated/subcap appetite: Management described MA as having strong demographic tailwinds and said they focus on growing the MA book via both attribution and performance; they reiterated preference for shared risk vs full capitation, citing reduced conflict and adaptability across ZIP code-level contracting.
  • Evolent integration and cross-sell into new states: Management said integration is ahead on schedule within the first three months post-close (December), with tech stack integration complete; cross-selling into the physician base takes time, with sales cycles cited as 3–6 months and implementations 4–6 months, so they did not break out sell-through figures.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the PRVA Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for PRVA.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (PRVA)

© 2026 Stock Market Info — Privia Health Group, Inc. (PRVA) Financial Profile